KURN.SW stock is trading at CHF 27.98, up 5.58% intraday on the SIX exchange on 05 Mar 2026 as investors position ahead of Kuros Biosciences AG’s earnings due 10 Mar 2026. Volume sits at 35,194 shares versus an average of 137,305, suggesting selective interest in the biotech name. With EPS at -0.15 and a negative PE, the upcoming report can meaningfully affect guidance, clinical updates and near-term valuation.

Intraday price action and key market data for KURN.SW stock

KURN.SW stock opened at CHF 27.72, hit a day low of CHF 27.28 and a day high of CHF 28.10 with the last print CHF 27.98. Market cap is CHF 1,073,403,220.00 and shares outstanding are 39,175,300. The 50-day average is CHF 26.59 and the 200-day average is CHF 27.24, showing the stock trading slightly above both short and medium term averages.

Earnings spotlight: what to watch in the 10 Mar report for KURN.SW stock

Kuros reports earnings on 10 Mar 2026 (scheduled announcement). Traders will focus on revenue versus guidance, R&D spend for KUR-111 and KUR-113 trials, and any commercial update for MagnetOs and Neuroseal. Given current EPS of -0.15, management commentary on cash runway and reimbursement in key markets will be decisive for near-term sentiment.

Fundamentals and valuation snapshot for KURN.SW stock

The company posts revenue per share CHF 2.69 and a negative net income per share CHF -0.15, yielding a trailing PE of -182.67. Key valuation ratios include price-to-sales 10.01 and price-to-book 14.23, reflecting a premium versus biotech sector medians. Kuros shows a healthy current ratio 2.25 but low free cash flow per share CHF -0.02, highlighting funding sensitivity.

Technical and sector context for KURN.SW stock

Momentum indicators are modestly constructive: RSI 57.52, MACD histogram 0.25, and ATR 1.13, supporting the intraday uptick. Healthcare (Switzerland) peer group trades with an average PE near 35.16; Kuros’s higher P/S and negative earnings mark it as a higher-risk biotech within the sector. Watch volume profile and the 50-day moving average slope for confirmation of the move.

Analyst signals, company rating and risk factors for KURN.SW stock

Third-party company rating dated 04 Mar 2026 shows a C- and a ‘Strong Sell’ recommendation on some screening models. Key risks include trial readouts, reimbursement delays and inventory turnover (days of inventory on hand 406.74). Upside hinges on clinical progress and commercial traction for MagnetOs and Neuroseal in the EU and US.

Meyka AI grade, forecast and price targets for KURN.SW stock

Meyka AI rates KURN.SW with a score out of 100: 72.27 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of CHF 35.84, a quarterly objective of CHF 23.22, and a monthly estimate of CHF 20.14. Compared with the current CHF 27.98, the 12‑month projection implies an upside of 28.08%. Forecasts are model-based projections and not guarantees.

Final Thoughts

KURN.SW stock is trading at CHF 27.98 intraday on 05 Mar 2026 as markets re-price ahead of Kuros Biosciences AG’s earnings on 10 Mar 2026. The company shows solid current assets and clear commercial products, but valuation metrics — price-to-sales 10.01 and price-to-book 14.23 — and negative EPS -0.15 point to execution risk. Market signals are mixed: technicals (RSI 57.52) support the move, while third-party screeners flagged a C- company rating on 04 Mar 2026. Our proprietary Meyka AI forecast sees CHF 35.84 in 12 months, an implied upside of 28.08% from today’s price, while nearer-term targets sit at CHF 23.22 and CHF 20.14 for the quarter and month. Investors should weigh clinical readouts, guidance on cash runway and revenue trajectory from MagnetOs and Neuroseal before acting. For an internal view and live updates see our Meyka stock page and Kuros investor resources Meyka KURN.SW page and Kuros Biosciences investor site. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.